Poor metabolic health increases COVID-19-related mortality in the

2	UK	Bio	bank	samp	le
---	----	-----	------	------	----

4 Short title

1

3

6

11

17

20

- 5 Metabolic health and COVID-19
- 7 Authors
- 8 Filip Morys¹, Alain Dagher¹
- ⁹ Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill
- 10 University, Montreal, Quebec, Canada
- 12 Correspondence
- 13 Alain Dagher
- 14 Montreal Neurological Institute
- 15 3801 University, H3A 2B4 Montreal, Canada
- 16 alain.dagher@mcgill.ca
- 18 Conflict of interest
- 19 The authors have declared that no competing interests exist
- 21 Keywords
- 22 Metabolic health, obesity, COVID-19

Abstract

Previous studies link obesity, components of metabolic health, such as hypertension or inflammation, to increased hospitalisations and death rates of patients with COVID-19. Here, in two overlapping samples of over 1,000 individuals from the UK Biobank we investigate whether metabolic health as measured by waist circumference, dyslipidaemia, hypertension, diabetes, and systemic inflammation is related to increased COVID-19 infection and mortality rates. Using logistic regression and controlling for confounding variables such as socioeconomic status, age, sex or ethnicity, we find that individuals with worse metabolic health (measured on average eleven years prior to 2020) have an increased risk for COVID-19-related death (adjusted odds ratio: 1.67). We also find that specific factors contributing to increased mortality are increased serum glucose levels, systolic blood pressure and waist circumference.

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Introduction Since the beginning of the COVID-19 pandemic, mounting evidence supports an association between obesity and poor outcomes (1-12). The association holds for both obesity and for obesity-associated metabolic health – hypertension, diabetes, dyslipidaemia, and systemic inflammation (13). Similarly, obesity and excess adipose tissue have also been associated with higher risk of SARS-CoV-2 infection (10,14,15).Previous studies, however, have tended to use small sample sizes, focus predominantly on the effects of body mass index (BMI) as a measure of obesity, or not account for confounding factors, such as ethnicity or socioeconomic status (14,16–18). Since ethnicity and socioeconomic status are themselves associated with obesity and metabolic health (19,20), they could confound interpretation of analyses in patients with COVID-19. Here, we aim to present a comprehensive evaluation of obesity-associated metabolic risk factors that might be related to poor health outcomes in SARS-CoV-2 infected patients while controlling for confounding variables and limiting potential collider bias. which has previously resulted in incorrect epidemiological conclusions (21-23). We investigate whether metabolic health is related to higher chance for SARS-CoV-2 infection, but also COVID-19-related death. **Materials and Methods Participants** In this study, we used the UK Biobank dataset – a large scale study with extensive

phenotyping carried out in the United Kingdom (24). This study was performed under

UK Biobank application ID 35605. SARS-CoV-2 real-time PCR test results in the UK

Biobank dataset are derived from the Public Health England microbiology database Second Generation Surveillance System that is dynamically linked to the UK Biobank database (25). Here we only included individuals who were recorded as tested for SARS-CoV-2. We distinguished between two samples for two aims of our project: Sample 1 – a larger sample (n=12,659) of all individuals who were tested for SARS-CoV-2 between 16th March 2020 and 24th August 2020, to investigate the risk of COVID-19 infection and how it is related to metabolic health; and Sample 2, a subset of Sample 1 consisting of individuals who tested positive for COVID-19 (n=1,152). We also obtained data on mortality from COVID-19 for all the individuals included in our study population. Sample characteristics can be found in Table 1. The discrepancies in number of patients who tested positive in both samples is due to outlier exclusions (see section: 'Measures used in the study'). All participants signed written informed consent prior to participating in the UK Biobank study, which was approved by the North-West Multi-centre Research Ethics Committee (11/NW/0382). All UK Biobank actions are overseen by the UK Biobank Ethics Advisory Committee.

Table 1 Participants characteristics.

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Measure	Sample 1 (n=12,659)			Sample 2 (n=1,152)		
	SARS-CoV-2	SARS-CoV-2	p-	SARS-CoV-2	SARS-CoV-2	p-
	positive patients	negative patients	value	survivors	deceased	value
	mean (SD)	mean (SD)		mean (SD)	mean (SD)	
n	1,138	11,521		972	180	
COVID-19 mortality rate	1.42%			15.63%		
Age in years	68 (8)	70 (8)	<0.001	67 (9)	74 (6)	<0.001
Sex distribution	47.36 % women	52.32 % women	0.002	49.07 % women	36.67 %	0.003
Waist circumference	93.38 (13.89)	92.07 (13.69)	0.003	92.55 (13.62)	98.62 (14.48)	<0.001
(cm)						

Serum HDL (mmol/l)	1.36 (0.34)	1.43 (0.38)	<0.001	1.37 (0.45)	1.35 (0.32)	0.446
Serum TG (mmol/l)	1.78 (1.04)	1.77 (1.02)	0.545	1.78 (1.05)	1.88 (1.01)	0.199
HbA1c (mmol/mol)	35.83 (4.51)	35.76 (4.33)	0.637	35.73 (4.62)	36.99 (5.23)	0.003
Serum glucose (mmol/l)	4.98 (0.64)	5.00 (0.63)	0.318	4.96 (0.63)	5.19 (0.74)	<0.001
Serum C-reactive protein	3.00 (5.23)	2.84 (4.45)	0.308	2.89 (5.14)	3.98 (7.22)	0.054
(mg/l)						
Systolic blood pressure	137.20 (18.59)	138.55 (18.55)	0.019	135.71 (18.15)	145.76 (18.33)	<0.001
(mmHg)						
Diastolic blood pressure	82.46 (10.25)	82.24 (9.94)	0.484	82.21 (10.31)	84.03 (10.03)	0.027
(mmHg)						
Diabetes	9.49 %	7.83 %	0.055	8.95 %	15.56 %	0.010
Hypertension	41.65 %	42.32 %	0.685	38.17 %	62.22 %	<0.001

82 SD – standard deviation, HDL – high density lipoprotein cholesterol, TG – triglycerides, HbA1C – haemoglobin A1c. P-values reflect significance of within samples differences calculated with t-tests in case of numerical variables and chi-squared tests in case of categorical variables.

Measures used in the study

To investigate how metabolic health is related to SARS-CoV-2 infection and mortality rates, we used the following measures: waist circumference, serum triglyceride (TG), serum high density lipoprotein cholesterol (HDL), glycated haemoglobin (HbA1c), serum glucose (corrected for fasting times prior to blood drawing), serum C-reactive protein (26), previous diabetes diagnosis, resting systolic and diastolic blood pressure (mean of two measurements each), and hypertension diagnosis. In our analyses, we also controlled for age, sex, socioeconomic status (Townsend deprivation index (27), highest achieved educational qualifications, mean family income), smoking status, and ethnic background, the laboratory where COVID-19 testing was performed, and the origin of the sample used for COVID-19 test (e.g. nose, throat etc.). For Sample 2, we also used mortality data provided by the UK Biobank – COVID-19-related death was described using the ICD10 identifier U07.1.

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

All variables related to metabolic health and all confounding variables were collected on average 11 years prior to COVID-19 tests. Prior to the analyses, all numeric variables were z-scored, all serum level values were log-transformed, and we excluded outliers from the samples (2.2 interquartile range below 1st or above 3rd quartile). If participants were tested for SARS-CoV-2 more than once, they were considered positive if at least one test result was positive. Statistical analyses The same analyses were performed for each of the two population samples. Data were analysed using R (v. 3.6.0). First, using confirmatory factor analysis in lavaan (v. 0.6-7), we estimated the fit of a latent variable 'metabolic health', which consisted of waist circumference, serum C-reactive protein levels, a latent variable 'dyslipidaemia' (serum HDL and TG levels; with loadings constrained to be equal between the two variables (28)), and two other latent variables, diabetes and hypertension. The latent variable 'diabetes' consisted of serum glucose and HbA1c levels, and diabetes diagnosis, while the latent variable 'hypertension' consisted of a blood pressure (systolic and diastolic blood pressure), and hypertension diagnosis (Figure 1). The model was estimated using robust maximum likelihood estimation and model's fit was evaluated using common indices: comparative fit index (CFI), root mean square error of approximation (RMSEA), and standardized root mean square residual (SRMR). Acceptable fit was defined as CFI>0.9, RMSEA<0.1, and SRMR<0.08. Next, we extracted components of the latent variable 'metabolic health' for each participant and entered them in a logistic regression. The outcome variable in logistic regression for Sample 1 was COVID-19 test result, while for Sample 2 the outcome variable was COVID-19-related death.

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

In the analyses we used a set of confounding variables to calculate adjusted odds ratio for testing positive for COVID-19: age, sex socioeconomic status, smoking status, ethnic background, test laboratory, and sample origin (6,29–31). Finally, for Sample 2 we explored how individual factors contributed to the COVID-19-related mortality by using a logistic regression with individual components of metabolic health, instead of the latent variable 'metabolic health'. Overall, analyses using a latent variables approach allowed us to maximize information shared between different measured variables within the same metabolic domains, e.g. serum glucose levels, HbA1C levels and diabetes diagnosis for the latent variable diabetes. Furthermore, adding continuous measures in this study, such as glucose levels or blood pressure levels, instead of only using diabetes or hypertension diagnosis, enabled us to use more information that is available in the dataset and investigate in depth how continuous metabolic health measures are related to SARS-CoV-2 infection and COVID-19 mortality rates. A script for the analysis of the data as well as the output of statistical software can be found at https://github.com/FilipMorys/COVID_MetS. Results Metabolic health and the risk of COVID-19 infections In Sample 1, the confirmatory factor analysis provided an acceptable model fit (CFI=0.932, RMSEA=0.065, SRMR=0.040). In the logistic regression the relation between metabolic health and the chance of having a positive SARS-CoV-2 test did not reach our pre-set statistical significance threshold (p=0.060; odds ratio 1.10; 95% confidence intervals (CI): 0.996-1.216). Metabolic health is related to an increased COVID-19-related mortality

Among the individuals who tested positive, 180 people (16%) died from COVID-19, allowing us to investigate how metabolic health influences COVID-19-related mortality. Here, the confirmatory factor analysis provided an acceptable model fit (CFI=0.923, RMSEA=0.071, SRMR=0.049). Logistic regression showed that obesityassociated metabolic impairment was related to an increased mortality rate among COVID-19 positive individuals (p=0.0006) – adjusted odds ratio: 1.67 (95% CI: 1.25-2.23), pointing to a 67% increase for each unit increase on the metabolic health latent variable (Figure 2). Each unit increase on the metabolic health variable means increased serum glucose levels by 0.20 mmol/l, glycated haemoglobin A1c levels by 3.26 mmol/mol, C-reactive protein levels by 2.14 mg/l, triglyceride levels by 0.67 mmol/l, systolic blood pressure by 7.16 mmHg, diastolic blood pressure by 4.22 mmHg, waist circumference by 18.74 cm, and decreased HDL cholesterol levels by 0.25 mmol/l. Exploratory analysis with individual components of metabolic health revealed that higher systolic blood pressure, higher serum glucose, and higher waist circumference increased the chance of COVID-19-related mortality - the adjusted odds ratio were 1.30 (95% CI: 1.01-1.68), 1.26 (95% CI: 1.04-1.54), and 1.36 (95% CI: 1.07-1.74), respectively (systolic blood pressure: p=0.044, glucose levels: p=0.018, waist circumference: p=0.014; Figure 2).

Discussion

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168 169

170

171

172

173

174

We investigated whether obesity-associated poor metabolic health, here defined by increased waist circumference, increased TG levels, decreased HDL levels, systemic inflammation, increased glucose and HbA1C levels, increased systolic and diastolic blood pressure, and the presence of diabetes and hypertension, is a risk factor for COVID-19 infection and mortality. We were able to show that a one unit

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

increase of the latent variable 'metabolic health' results in a 67% higher risk of death because of COVID-19. In contrast, the relation between metabolic health and the likelihood of test positivity was weaker, with an odds ratio of only 1.1 and a confidence interval that included the null effect. In sum, poor metabolic health contributes little to no risk of test positivity but substantially increases the odds of an adverse outcome. A strength of our analysis lies in the fact that the risk factor variables were measured prior to COVID-19 diagnosis and therefore were not influenced by the disease itself or possible treatment. Another is that we controlled for known shared risk factors between obesity and COVID-19 outcomes, such as socioeconomic status, ethnicity, and sex. The results of our study are in line with previous reports linking obesity and individual components of metabolic health with poor COVID-19 outcomes and death (1,5,7,10,12,18,32). Bansal et al. review some of the physiological mechanisms that might mediate the relationship between obesity, related comorbidities and worse outcomes of COVID-19 (33). These include an enhanced expression of the (ACE2), diabetes-related angiotensin converting enzyme 2 microvascular dysfunction, increased expression of pro-inflammatory cytokines, or activation of the renin-angiotensin-aldosterone system related to hypertension (33–35). Recent reports especially highlight the role of interleukin-6 (IL-6) in the pathogenesis of COVID-19, but also the role of IL-6 inhibitors in COVID-19 therapy (36,37). This is important given that adiposity is associated with chronic systemic inflammation, which generally delays immune response to pathogens and can also lead to worse outcomes in COVID-19 patients (35,38-40). In general, our results suggest that a number of these mechanisms might also contribute to increased mortality rates from COVID-19.

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

Previous studies investigating COVID-19 in the UK Biobank used positive test results obtained between March 16th and April 26th as a proxy of severe COVID-19 (18,41). The rationale for this is that, during this time, only patients admitted to hospitals and with COVID-19-like symptoms were tested for SARS_CoV-2. Here, we decided to not use this approach for several reasons. First, it is possible that individuals with COVID-19-like symptoms for which they were admitted to a hospital but who did not have COVID-19 were only infected after being admitted. In those cases, positive tests would not reflect COVID-19 severity. Second, it is not possible to determine the exact reason for which inpatients were tested for SARS-CoV-2; positive test results might therefore not only reflect severity of COVID-19 disease, but also testing in anticipation of isolating patients admitted for other reasons. For example, patients having to undergo unrelated medical procedures might have undergone precautionary testing. We therefore recommend that studies that used this approach as a proxy for COVID-19 severity be interpreted with caution. For the interpretation of our and similar results from the UK Biobank, it is important to note that the UK Biobank is not a sample representative of the entire UK population and therefore the findings might not be generalizable (42). Infection and mortality rates calculated here should not be used as an indicator of true prevalence and mortality rate in the general population. Furthermore, observational studies such as ours are prone to collider bias, which has already been identified in UK Biobank COVID-19 investigations (23). Collider bias occurs when the sample population is conditioned on a variable that correlates with the variables of interest. For example, during the time period of the current study, it is thought that health workers were more likely to be tested for SARS-CoV-2, which may have contributed to incorrect conclusion that cigarette smoking is protective, as health care workers have a lower

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

incidence of smoking (23). Our study population includes individuals who were seen in a health care setting, who may therefore have a higher incidence of obesity and poorer metabolic health than the general population. However, it is difficult to see how this would account for the effect of obesity on death from COVID-19 among people who tested positive for the virus. In addition, COVID-19 testing in the UK during the time period of this study was generally restricted to individuals with symptoms such as fever, cough, or loss of smell or taste – asymptomatic COVID-19 individuals were less likely to be tested. This might further increase the extent of collider bias in this and similar studies investigating the predictors of COVID-19 severity or mortality. Current strategies to account for such bias or measure the extent thereof rely on models and strong assumptions that might be incorrect. We therefore suggest that our findings be interpreted with caution. Nonetheless, our model did account for potential collider variables or confounds such as socioeconomic status, ethnicity and age. Finally, in this study we only used limited data pertaining to COVID-19 diagnosis or mortality. The seriousness of illness, treatment administered, or actual cause of death were not investigated here. In sum, we used the UK Biobank dataset to confirm that, in individuals who tested positive for COVID-19 in the early stages of the pandemic, metabolic health, and especially visceral adiposity, hypertension, and serum glucose levels, were associated with an increased risk of death.

Funding

This work was supported by a Foundation Scheme award to AD from the Canadian Institutes of Health Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Figures




Figure 1 Confirmatory factor analysis model used to derive the latent variable 'metabolic health. Squares indicate measured variables; circles indicate latent variables. HbA1c – glycated haemoglobin A1c; HDL – high density lipoprotein cholesterol; TG – triglycerides; CRP – C-reactive protein.




Figure 2 Odds ratio for COVID-19-related death. Circles represent adjusted odds ratios, error bars represent 95% confidence intervals.

266 References 267 Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 268 Mortality. Obesity (2020) 28:1005. doi:10.1002/oby.22818 269 2. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired 270 metabolic health in patients with COVID-19. Nat Rev Endocrinol (2020) 271 **16**:341–342. doi:10.1038/s41574-020-0364-6 272 3. Deng L, Zhang J, Wang M, Chen L. Obesity is associated with severe COVID-273 19 but not death: a dose-response meta-analysis. *Epidemiol Infect* (2021)1– 274 27. doi:10.1017/S0950268820003179 275 4. Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, Zhao HL. Obesity in 276 patients with COVID-19: a systematic review and meta-analysis. Metabolism 277 (2020) **113**:154378. doi:10.1016/j.metabol.2020.154378 278 5. Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, Chen YP, Targher G, 279 Byrne CD, George J, et al. Obesity Is a Risk Factor for Greater COVID-19 280 Severity. Diabetes Care (2020) 43:E72–E74. doi:10.2337/dc20-0682 281 6. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of 282 obesity and its genetic predisposition with the risk of severe COVID-19: 283 Analysis of population-based cohort data. *Metabolism* (2020) **112**:154345. 284 doi:10.1016/j.metabol.2020.154345 285 7. Zhao X, Gang X, He G, Li Z, Lv Y, Han Q, Wang G. Obesity Increases the 286 Severity and Mortality of Influenza and COVID-19: A Systematic Review and 287 Meta-Analysis. Front Endocrinol (Lausanne) (2020) 11:1007. 288 doi:10.3389/fendo.2020.595109 289 8. Martos-Benítez FD, Soler-Morejón CD, García-del Barco D. Chronic

comorbidities and clinical outcomes in patients with and without COVID-19: a

291 large population-based study using national administrative healthcare open 292 data of Mexico. Intern Emerg Med (2021)1. doi:10.1007/s11739-020-02597-5 293 9. Breland JY, Wong MS, Steers WN, Yuan AH, Haderlein TP, Washington DL. 294 Body Mass Index and Risk for Severe COVID-19 among Veterans Health 295 Administration Patients. Obesity (2021) oby.23121. doi:10.1002/oby.23121 296 10. Jayawardena R. Jeyakumar DT, Misra A, Hills AP, Ranasinghe P. Obesity: A 297 potential risk factor for infection and mortality in the current COVID-19 298 epidemic. Diabetes Metab Syndr Clin Res Rev (2020) 14:2199–2203. 299 doi:10.1016/j.dsx.2020.11.001 300 Chiappetta S, Sharma AM, Bottino V, Stier C. COVID-19 and the role of 11. 301 chronic inflammation in patients with obesity. Int J Obes (2020) 44:1790–1792. 302 doi:10.1038/s41366-020-0597-4 303 12. Peña JE de la, Rascón-Pacheco RA, Ascencio-Montiel I de J, González-304 Figueroa E, Fernández-Gárate JE, Medina-Gómez OS, Borja-Bustamante P, 305 Santillán-Oropeza JA, Borja-Aburto VH. Hypertension, Diabetes and Obesity, 306 Major Risk Factors for Death in Patients With COVID-19 in Mexico. Arch Med 307 Res (2020) doi:10.1016/i.arcmed.2020.12.002 308 13. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, 309 Fruchart JC, James WP, Loria CM, Smith Jr SC, et al. Harmonizing the 310 metabolic syndrome: a joint interim statement of the International Diabetes 311 Federation Task Force on Epidemiology and Prevention; National Heart, Lung, 312 and Blood Institute; American Heart Association; World Heart Federation; 313 International. *Circulation* (2009) **120**:1640–1645. 314 doi:10.1161/CIRCULATIONAHA.109.192644 315 14. Yates T, Razieh C, Zaccardi F, Davies MJ, Khunti K. Obesity and risk of

316 COVID-19: analysis of UK biobank. *Prim Care Diabetes* (2020) 317 doi:10.1016/j.pcd.2020.05.011 de Frel DL, Atsma DE, Pijl H, Seidell JC, Leenen PJM, Dik WA, van Rossum 318 15. 319 EFC. The Impact of Obesity and Lifestyle on the Immune System and 320 Susceptibility to Infections Such as COVID-19. Front Nutr (2020) 7:597600. 321 doi:10.3389/fnut.2020.597600 322 Townsend MJ, Kyle TK, Stanford FC. Outcomes of COVID-19: disparities in 16. 323 obesity and by ethnicity/race. *Int J Obes* (2020) **44**:1807–1809. 324 doi:10.1038/s41366-020-0635-2 325 Xie J, Zu Y, Alkhatib A, Pham TT, Gill F, Jang A, Radosta S, Chaaya G, Myers 17. 326 L, Zifodya JS, et al. Metabolic Syndrome and COVID-19 Mortality Among Adult 327 Black Patients in New Orleans. *Diabetes Care* (2020)dc201714. 328 doi:10.2337/dc20-1714 329 18. Hamer M, Gale CR, Kivimäki M, Batty GD. Overweight, obesity, and risk of 330 hospitalization for COVID-19: A community-based cohort study of adults in the 331 United Kingdom. Proc Natl Acad Sci (2020)202011086. 332 doi:10.1073/pnas.2011086117 333 Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. 19. 334 Gastroenterol Clin North Am (2016) 45:571–579. doi:10.1016/j.gtc.2016.07.012 335 336 20. Pigeyre M, Rousseaux J, Trouiller P, Dumont J, Goumidi L, Bonte D, Dumont MP, Chmielewski A, Duhamel A, Amouyel P, et al. How obesity relates to 337 338 socio-economic status: Identification of eating behavior mediators. Int J Obes 339 (2016) **40**:1794–1801. doi:10.1038/ijo.2016.109 340 21. Gaibazzi N, Tuttolomondo D, Guidorossi A, Botti A, Tedeschi A, Martini C,

341 Mattioli M. Smoking Prevalence is Low in Symptomatic Patients Admitted for 342 COVID-19. Cold Spring Harbor Laboratory Press (2020). 343 doi:10.1101/2020.05.05.20092015 344 22. Miyara M, Tubach F, POURCHER V, Morelot-Panzini C, Pernet J, Haroche J, 345 Lebbah S, Morawiec E, Gorochov G, Caumes E, et al. Low rate of daily active 346 tobacco smoking in patients with symptomatic COVID-19. Qeios (2020) 347 doi:10.32388/wpp19w.4 Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, Sharp GC, 348 23. 349 Sterne J, Palmer TM, Davey Smith G, et al. Collider bias undermines our 350 understanding of COVID-19 disease risk and severity. *Nat Commun* (2020) 351 **11**:5749. doi:10.1038/s41467-020-19478-2 352 24. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott 353 P, Green J, Landray M, et al. UK Biobank: An Open Access Resource for 354 Identifying the Causes of a Wide Range of Complex Diseases of Middle and 355 Old Age. PLOS Med (2015) 12:e1001779. doi:10.1371/journal.pmed.1001779 356 25. Armstrong J, Rudkin JK, Allen N, Crook DW, Wilson DJ, Wyllie DH, O'connell 357 AM. Dynamic linkage of covid-19 test results between public health england's 358 second generation surveillance system and uk biobank. Microb Genomics 359 (2020) **6**:1–9. doi:10.1099/mgen.0.000397 360 Elliott P, Peakman TC, UK Biobank. The UK Biobank sample handling and 26. 361 storage protocol for the collection, processing and archiving of human blood 362 and urine. Int J Epidemiol (2008) **37**:234–44. doi:10.1093/ije/dym276 363 27. Townsend P, Phillimore P, Beattie A. Health and Deprivation: Inequality and 364 the North. Croom Helm (1988). Available at: 365 https://books.google.ca/books?id=K9kOAAAAQAAJ

366	28.	Little TD, Lindenberger U, Nesselroade JR. On selecting indicators for
367		multivariate measurement and modeling with latent variables: When "good"
368		indicators are bad and "bad" indicators are good. Psychol Methods (1999)
369		4 :192–211. doi:10.1037/1082-989X.4.2.192
370	29.	Wu Z, McGoogan JM. Characteristics of and Important Lessons from the
371		Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a
372		Report of 72314 Cases from the Chinese Center for Disease Control and
373		Prevention. JAMA - J Am Med Assoc (2020) 323 :1239–1242.
374		doi:10.1001/jama.2020.2648
375	30.	Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ,
376		Campion TR, Nahid M, Ringel JB, et al. Clinical Characteristics of Covid-19 in
377		New York City. N Engl J Med (2020) 382 :2372–2374.
378		doi:10.1056/nejmc2010419
379	31.	Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin
380		KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital
381		admission and critical illness among 5279 people with coronavirus disease
382		2019 in New York City: Prospective cohort study. BMJ (2020) 369:
383		doi:10.1136/bmj.m1966
384	32.	Costa FF, Rosário WR, Ribeiro Farias AC, de Souza RG, Duarte Gondim RS,
385		Barroso WA. Metabolic syndrome and COVID-19: An update on the
386		associated comorbidities and proposed therapies. Diabetes Metab Syndr Clin
387		Res Rev (2020) 14 :809–814. doi:10.1016/j.dsx.2020.06.016
388	33.	Bansal R, Gubbi S, Muniyappa R. Metabolic Syndrome and COVID 19:
389		Endocrine-Immune-Vascular Interactions Shapes Clinical Course.
390		Endocrinology (2020) 161:1–15. doi:10.1210/endocr/bqaa112

391 34. Abu-Farha M, Al-Mulla F, Thanaraj TA, Kavalakatt S, Ali H, Abdul Ghani M, 392 Abubaker J. Impact of Diabetes in Patients Diagnosed With COVID-19. Front 393 Immunol (2020) 11:3112. doi:10.3389/fimmu.2020.576818 394 Mohammad S, Aziz R, Al Mahri S, Malik SS, Haji E, Khan AH, Khatlani TS, 35. 395 Bouchama A. Obesity and COVID-19: what makes obese host so vulnerable? 396 Immun Ageing (2021) **18**:1–10. doi:10.1186/s12979-020-00212-x 397 36. Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of 398 severe COVID-19. Biomed Pharmacother (2020) 131:110698. 399 doi:10.1016/j.biopha.2020.110698 400 37. Sinha P, Mostaghim A, Bielick CG, McLaughlin A, Hamer DH, Wetzler LM, 401 Bhadelia N, Fagan MA, Linas BP, Assoumou SA, et al. Early administration of 402 interleukin-6 inhibitors for patients with severe COVID-19 disease is 403 associated with decreased intubation, reduced mortality, and increased 404 discharge. Int J Infect Dis (2020) **99**:28–33. doi:10.1016/j.ijid.2020.07.023 405 38. Costa FF, Rosário WR, Ribeiro Farias AC, de Souza RG, Duarte Gondim RS, 406 Barroso WA. Metabolic syndrome and COVID-19: An update on the 407 associated comorbidities and proposed therapies. Diabetes Metab Syndr Clin 408 Res Rev (2020) **14**:809–814. doi:10.1016/j.dsx.2020.06.016 409 39. Morys F, Dadar M, Dagher A. Obesity impairs cognitive function via metabolic 410 syndrome and cerebrovascular disease: an SEM analysis in 15,000 adults 411 from the UK Biobank. bioRxiv (2020)2020.06.26.174086. 412 doi:10.1101/2020.06.26.174086 413 40. Bansal R, Gubbi S, Muniyappa R. Metabolic Syndrome and COVID 19: 414 Endocrine-Immune-Vascular Interactions Shapes Clinical Course. 415 Endocrinology (2020) **161**:1–15. doi:10.1210/endocr/bqaa112

Kuo C-L, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, Melzer D. 416 41. 417 APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. Journals Gerontol Ser A (2020) XX:1-2. doi:10.1093/gerona/glaa131 418 42. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, 419 Allen NE. Comparison of Sociodemographic and Health-Related 420 421 Characteristics of UK Biobank Participants with Those of the General 422 Population. Am J Epidemiol (2017) 186:1026–1034. doi:10.1093/aje/kwx246 423